Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 injection in renal impairment
NCT07141030Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bofanglutide in obesity, sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 36 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Observation Time-Point at 36 days and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
bofanglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07141030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141030.